Comparative Pharmacology
Head-to-head clinical analysis: ALCAFTADINE versus CHILDREN S ALAWAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALCAFTADINE versus CHILDREN S ALAWAY.
ALCAFTADINE vs CHILDREN'S ALAWAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective histamine H1 receptor antagonist; inhibits histamine release from mast cells and reduces ocular itch associated with allergic conjunctivitis.
Competitive antagonist of H1 histamine receptors, inhibiting histamine-mediated allergic responses; also blocks muscarinic acetylcholine receptors, contributing to anticholinergic effects.
1 drop of 0.25% ophthalmic solution in each affected eye twice daily.
Children's Alaway (ketotifen fumarate ophthalmic solution) is approved for children aged 3 years and older. The typical dose is 1 drop in the affected eye(s) twice daily, approximately every 8-12 hours. There is no standard adult dose as the product is indicated only for pediatric use.
None Documented
None Documented
Clinical Note
moderateAlcaftadine + Betahistine
"The therapeutic efficacy of Betahistine can be decreased when used in combination with Alcaftadine."
Clinical Note
moderateAmphetamine + Alcaftadine
"Amphetamine may decrease the sedative activities of Alcaftadine."
Clinical Note
moderateDiethylpropion + Alcaftadine
"Diethylpropion may decrease the sedative activities of Alcaftadine."
Clinical Note
moderatePhentermine + Alcaftadine
Terminal elimination half-life is approximately 2 hours (range 1.5–3 h) after topical ocular administration, appropriate for twice-daily dosing.
Terminal elimination half-life 2.5–3.5 hours in children; prolonged in renal impairment or neonates.
Primarily renal (approximately 50% unchanged), with the remainder as metabolites; negligible biliary/fecal elimination.
Primarily renal (approx. 90%) as unchanged drug and glucuronide conjugates; minimal biliary/fecal elimination (<5%).
Category C
Category C
Ophthalmic Antihistamine
Ophthalmic Antihistamine
"Phentermine may decrease the sedative activities of Alcaftadine."